Free Trial
LON:REDX

Redx Pharma (REDX) Share Price, News & Analysis

Redx Pharma logo
GBX 15
+3.60 (+31.58%)
(As of 04/30/2024)

About Redx Pharma Stock (LON:REDX)

Key Stats

Today's Range
11.42
33
50-Day Range
15
15
52-Week Range
4
37.90
Volume
1.42 million shs
Average Volume
707,637 shs
Market Capitalization
£58.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Receive REDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter.

REDX Stock News Headlines

Big Pharma lacks motive to prep for new pandemics
A new way to play the AI boom (act before November 19)
There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as little as $16 and a brokerage account.
Redx Pharma Plc Shares now trading on JP Jenkins
Redx Pharma PLC REDX
See More Headlines

REDX Stock Analysis - Frequently Asked Questions

Redx Pharma's stock was trading at GBX 22 at the beginning of the year. Since then, REDX stock has decreased by 31.8% and is now trading at GBX 15.
View the best growth stocks for 2024 here
.

Redx Pharma Plc (LON:REDX) announced its quarterly earnings results on Monday, November, 19th. The company reported ($7.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.50) by $0.50.

Shares of REDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Redx Pharma investors own include AutoZone (AZO), Barclays (BARC), Salesforce (CRM), Digital Globe Services (DGS), Intel (INTC), Legal & General Group (LGEN) and OptiBiotix Health (OPTI).

Company Calendar

Last Earnings
11/19/2018
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
101
Year Founded
N/A

Profitability

Net Income
£-33,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£4.20 million
Cash Flow
GBX 2.87 per share
Book Value
GBX 1 per share

Miscellaneous

Free Float
N/A
Market Cap
£58.35 million
Optionable
Not Optionable
Beta
-0.53
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (LON:REDX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners